Update on the diagnosis and management of hypophysitis

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 19, Issue 4, 2012, Pages 314-321

  Carmichael, John D ^a  

^a Pituitary Center   (United States)

Author keywords

Antipituitary antibodies; Cytotoxic T lymphocyte antigen 4 antibody related hypophysitis; Lymphocytic hypophysitis; Pituitary autoimmunity

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DEXAMETHASONE; GLUCOCORTICOID; IMMUNOGLOBULIN G4; IPILIMUMAB; METHYLPREDNISOLONE; TICILIMUMAB;

ADRENAL INSUFFICIENCY; AMENORRHEA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER SURVIVAL; CANCER THERAPY; COLON CANCER; DIARRHEA; DIPLOPIA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; FOOD AND DRUG ADMINISTRATION; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS DISEASE; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHYROIDISM; IMMUNE RESPONSE; KIDNEY CARCINOMA; LIVER TOXICITY; LYMPHOCYTIC INFILTRATION; METASTASIS; METASTATIC MELANOMA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; TUMOR CELL;

AUTOIMMUNE DISEASES; CTLA-4 ANTIGEN; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INFLAMMATION; MALE; PITUITARY DISEASES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84864604895     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32835430ed     Document Type: Article

References (47)

1. Caturegli P, Newschaffer C, Olivi A, et al. Autoimmune hypophysitis. Endocr Rev 2005; 26:599-614.
2. Buxton N, Robertson I. Lymphocytic and granulocytic hypophysitis: a single centre experience. Br J Neurosurg 2001; 15:242-245; discussion 245-246.
3. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010; 13:29-38.
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
5. Kahler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges 2011; 9:277-286.
6. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-6053.
7. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24:2283-2289.
8. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12:1005-1016.
9. Dillard T, Fleseriu M. Lymphocytic Hypophysitis after Treatment with Ipilimumab for Prostate Cancer. In: Western Regional Meeting. Carmel, CA; 2009.
10. Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011; 29:489-498.
11. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
12. Min L, Vaidya A, Becker C. Ipilimumab therapy for advanced melanoma is associated with secondary adrenal insufficiency: a case series. Endocr Pract 2011. [Epub ahead of print]
13. Barnard ZR, Walcott BP, Kahle KT, et al. Hyponatremia associated with ipilimumab-induced hypophysitis. Med Oncol 2012; 29:374-377.
14. Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immunerelated adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 2011; 197:W992-W1000.
15. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28:593-598.
16. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13:6681-6688.
17. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33:828-833.
18. De Bellis A, Pane E, Bellastella G, et al. Detection of antipituitary and antihypothalamus antibodies to investigate the role of pituitary or hypothalamic autoimmunity in patients with selective idiopathic hypopituitarism. Clin Endocrinol (Oxf) 2011; 75:361-366.
19. Guaraldi F, Caturegli P, Salvatori R. Prevalence of antipituitary antibodies in acromegaly. Pituitary 2011. [Epub ahead of print]
20. Landek-Salgado MA, Leporati P, Lupi I, et al. Growth hormone and proopiomelanocortin are targeted by autoantibodies in a patient with biopsyproven IgG4-related hypophysitis. Pituitary 2011. [Epub ahead of print].
21. Lupi I, Manetti L, Raffaelli V, et al. Pituitary autoimmunity is associated with hypopituitarism in patients with primary empty sella. J Endocrinol Invest 2011; 34:e240-e244.
22. Smith CJ, Oscarson M, Ronnblom L, et al. TSGA10: A target for autoantibodies in autoimmune polyendocrine syndrome type 1 and systemic lupus erythematosus. Scand J Immunol 2011; 73:147-153.
23. Smith CJ, Bensing S, Burns C, et al. Identification of TPIT and other novel autoantigens in lymphocytic hypophysitis; immunoscreening of a pituitary cDNA library and development of immunoprecipitation assays. Eur J Endocrinol 2012; 166:391-398.
24. Tanriverdi F, De Bellis A, Battaglia M, et al. Investigation of antihypothalamus and antipituitary antibodies in amateur boxers: is chronic repetitive head trauma-induced pituitary dysfunction associated with autoimmunity? Eur J Endocrinol 2010; 162:861-867.
25. Yamamoto M, Iguchi G, Takeno R, et al. Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humans. J Clin Invest 2011; 121:113-119.
26. Delvecchio M, De Bellis A, Francavilla R, et al. Antipituitary antibodies in children with newly diagnosed celiac disease: a novel finding contributing to linear-growth impairment. Am J Gastroenterol 2010; 105:691-696.
27. Bellastella G, Rotondi M, Pane E, et al. Predictive role of the immunostaining pattern of immunofluorescence and the titers of antipituitary antibodies at presentation for the occurrence of autoimmune hypopituitarism in patients with autoimmune polyendocrine syndromes over a five-year follow-up. J Clin Endocrinol Metab 2010; 95:3750-3757.
28. Lupi I, Zhang J, Gutenberg A, et al. From pituitary expansion to empty sella: disease progression in a mouse model of autoimmune hypophysitis. Endocrinology 2011; 152:4190-4198.
29. Zoeller GK, Benveniste RJ, Farhadi FA, et al. Lymphocytic hypophysitis in a patient presenting with sequential episodes of optic neuritis. Pituitary 2012; 15:101-105.
30. Luo C, Lu Y, Jiang L, Wu X. Castleman's disease with autoimmune hypophysitis. Acta Neurochir (Wien) 2010; 152:1811-1812.
31. Leporati P, Landek-Salgado MA, Lupi I, et al. IgG4-related hypophysitis: a new addition to the hypophysitis spectrum. J Clin Endocrinol Metab 2011; 96: 1971-1980.
32. Hori M, Makita N, Andoh T, et al. Long-term clinical course of IgG4-related systemic disease accompanied by hypophysitis. Endocr J 2010; 57:485-492.
33. Patel SM, Szostek JH. IgG4-related systemic disease in a Native American man. Intern Med 2011; 50:931-934.
34. Quintos JB, Grover M, Boney CM, Salas M. Autoimmune polyglandular syndrome type 3 and growth hormone deficiency. Pediatr Diabetes 2010; 11:438-442.
35. Ferrante E, Giavoli C, Elli L, et al. Evaluation of GH-IGF-I axis in adult patients with coeliac disease. Horm Metab Res 2010; 42:45-49.
36. Giavoli C, Ferrante E, Bergamaschi S, et al. An unusual case of recurrent autoimmune hypophysitis. Exp Clin Endocrinol Diabetes 2010; 118:287-290.
37. Lecube A, Francisco G, Rodr?́guez D, et al. Lymphocytic hypophysitis successfully treated with azathioprine: first case report. J Neurol Neurosurg Psychiatry 2003; 74:1581-1583.
38. Tubridy N, Saunders D, Thom M, et al. Infundibulohypophysitis in a man presenting with diabetes insipidus and cavernous sinus involvement. J Neurol Neurosurg Psychiatry 2001; 71:798-801.
39. Ward L, Paquette J, Seidman E, et al. Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. J Clin Endocrinol Metab 1999; 84:844-852.
40. Yang GQ, Lu ZH, Gu WJ, et al. Recurrent autoimmune hypophysitis successfully treated with glucocorticoids plus azathioprine: a report of three cases. Endocr J 2011; 58:675-683.
41. Curto L, Torre ML, Cotta OR, et al. Lymphocytic hypophysitis: differential diagnosis and effects of high-dose pulse steroids, followed by azathioprine, on the pituitary mass and endocrine abnormalities: report of a case and literature review. ScientificWorldJournal 2010; 10:126-134.
42. Papanastasiou L, Pappa T, Tsiavos V, et al. Azathioprine as an alternative treatment in primary hypophysitis. Pituitary 2011; 14:16-22.
43. Lu Z, Yang G, Ba J, et al. Spontaneous pregnancy in a patient with a relapse of lymphocytic hypophysitis successfully treated with azathioprine and glucocorticoids. Endocrine 2011; 39:296-297.
44. Selch MT, DeSalles AA, Kelly DF, et al. Stereotactic radiotherapy for the treatment of lymphocytic hypophysitis. Report of two cases. J Neurosurg 2003; 99:591-596.
45. Leung GK, Lopes MB, Thorner MO, et al. Primary hypophysitis: a single-center experience in 16 cases. J Neurosurg 2004; 101:262-271.
46. Ray DK, Yen CP, Vance ML, et al. Gamma knife surgery for lymphocytic hypophysitis. J Neurosurg 2010; 112:118-121.
47. Howlett TA, Levy MJ, Robertson IJ. How reliably can autoimmune hypophysitis be diagnosed without pituitary biopsy. Clin Endocrinol (Oxf) 2010; 73:18-21.